Report : North America Manufacturing Execution System (MES) In Life Sciences Market Forecast to 2033 - COVID-19 Impact and Regional Analysis by Offering (Software and Services), Deployment (On-Premises and Cloud), Organization Size (SMEs and Large Enterprises), and Application (Pharmaceutical, Biotechnology, and Medical Devices)
At 11.5% CAGR, the North America Manufacturing Execution System (MES) In Life Sciences Market is speculated to be worth US$ 3,360.73 million by 2033, says Business Market Insights
According to Business Market Insights research, the North America manufacturing execution system in life sciences market was valued at US$ 1,128.71 million in 2023 and is expected to reach US$ 3,360.73 million by 2033, registering a CAGR of 11.5% from 2023 to 2033. Need for compliances with regulatory framework and requirement of accurate real-time data in production management process are the critical factors attributed to the North America manufacturing execution system in life sciences market expansion.
Pharmaceutical and medical device manufacturers face various challenges in a drastically changing landscape. Protectionist trade policies are creating supply chain challenges while increased state interventions are promoting regionalization. High inflation across several countries is increasing labor, raw materials, and transportation costs. The pharma industry is also facing talent shortages linked to broader labor market trends, including the 20% increase in demand for science, technology, engineering, and mathematics (STEM) related roles across the life sciences industry in the US. The product landscape is also changing rapidly, with new modalities such as cell and gene therapy (CGT) and mRNA vaccine technology witnessing a high percent rise in the drug development pipeline. Despite being renowned for holding high inventory levels and long-standing dual-sourcing policies, the changing landscape has led pharmaceutical and medical device manufacturers to optimize their business processes, including adopting MES. Previously used paper-based systems are becoming obsolete as a larger emphasis is being laid upon gathering real-time data for improving process flow and reducing operational costs. MES can help manufacturers to function with a lower workforce, gather accurate real-time data from the production process, increase process efficiency and flexibility, safeguard regulatory expectations, and digitize the manufacturing process. For instance, in February 2022, Integer, a medical device outsource (MDO) manufacturer, announced that it had selected Critical Manufacturing’s Manufacturing Execution System (MES) to enhance the quality and efficiency of its global production processes. The company will implement this module at its site in Ireland to digitalize its production processes; gather real-time data; and add efficiency, quality, and traceability. Similarly, in September 2020, Korber and Walvax Biotechnology announced that it had signed an agreement to implement Werum PAS-X MES, the MES for pharma, biotech, and cell & gene therapy manufacturing, at its Yuxi plant for vaccine production. As per Korber, PAS-X MES allows the user to manage, visualize and analyze data fast, comprehensively, and in real time. In addition, modern MES solutions (often referred to as light MES) are highly flexible, tailored as per requirements, integrate various tools, and are cloud-based. Further, the MES and Laboratory Execution Systems (LES) can also help reduce the risk of contamination, improve data integrity, lower operating costs, ensure regulatory compliance and quality, and enhance track and trace capabilities. Because of all the above advantages of using MES, various market players are adopting the system.
On the contrary, high cost and lack of flexibility hampers the North America Manufacturing Execution System (MES) In Life Sciences Market.
Based on offering, the North America manufacturing execution system in life sciences market is segmented into software and services. The services segment held 72.6% share of North America Manufacturing Execution System (MES) In Life Sciences Market in 2023, amassing US$ 818.94 million. It is projected to garner US$ 2,517.46 million by 2033 to expand at 11.9% CAGR during 2023–2033.
Based on deployment, the North America manufacturing execution system in life sciences market is segmented into on-premises and cloud. The cloud segment held 50.7% share of North America Manufacturing Execution System (MES) In Life Sciences Market in 2023, amassing US$ 572.36 million. It is projected to garner US$ 2,269.64 million by 2033 to expand at 14.8% CAGR during 2023–2033.
Based on organization size, the North America manufacturing execution system in life sciences market is segmented into SMEs and large enterprises. The large enterprises segment held 75.9% share of North America Manufacturing Execution System (MES) In Life Sciences Market in 2023, amassing US$ 856.85 million. It is projected to garner US$ 2,510.99 million by 2033 to expand at 11.4% CAGR during 2023–2033.
Based on application, the North America manufacturing execution system in life sciences market is segmented into pharmaceutical, biotechnology, and medical devices. The medical devices segment held 46.8% share of North America Manufacturing Execution System (MES) In Life Sciences Market in 2023, amassing US$ 528.16 million. It is projected to garner US$ 1,577.94 million by 2033 to expand at 11.6% CAGR during 2023–2033.
Based on country, the North America manufacturing execution system in life sciences market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 69.0% share of North America Manufacturing Execution System (MES) In Life Sciences Market in 2023. It was assessed at US$ 778.48 million in 2023 and is likely to hit US$ 2,373.68 million by 2033, exhibiting a CAGR of 11.8% during the forecast period.
Key players dominating the North America manufacturing execution system in life sciences market are Apprentice FS Inc; Atachi Systems; ATS Global B.V.; Emerson Electric Co; LZ Lifescience Limited; POMS Corporation; Rockwell Automation Inc; Schneider Electric SE; and Siemens AG, among others.
- Jan 2023, Autolomous LTD—a developer of critical manufacturing management systems for Cell and Gene Therapies (CGT)—announced a license agreement with US-based Center for Breakthrough Medicines (CBM), a cell and gene therapy contract development, manufacturing, and testing organization (CDMO). The agreement allowed Autolomous to design, configure and integrate solutions for CBM utilizing the AutoloMATE platform. It is a business-critical robust digital system, providing CBM with seamless digital connectivity in the manufacturing operations across all critical elements (e.g., facility systems, technologies) for the end-to-end cell and gene therapy (CGT) value chain.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com